Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its lead CD19 targeting candidate, azercabtagene zapreleucel (azer-cel; PBCAR0191) for post-auto CAR T patients with non-Hodgkin lymphoma.